Microsynth Austria is an Austrian subsidiary of Microsynth AG and is located at the Biotechnology Center in Vienna. The parent company has it's headquarter in Balgach, Switzerland, and operates further subsidiaries in Germany (Microsynth Seqlab) and France (Microsynth France). Altogether Microsynth employs a staff of more than 100 people.
RIANA Therapeutics' approach to drug discovery is based on its proprietary platform technology for discovering compounds that target cancer-promoting protein-protein interactions (PPIs). Using this novel approach, RIANA is searching for inhibitors that block the formation of specific oncogenic PPIs. RIANA is currently working to develop new compounds that specifically target acute myeloid leukemia (AML) as well as other blood cancers and certain types of solid tumors.
CALYXHA develops novel small-molecule anti-inflammatory drugs
Marinomed Biotech AG is a biopharmaceutical company focused on inventing, developing, and partnering clinically meaningful therapies for patients suffering from serious viral infectious diseases and autoreactive immune disorders. Since its foundation in 2006, Marinomed has launched two powerful technologies (Carragelose® and Marinosolv®) with promising product candidates in the pipeline and a great potential for developing drugs that target diseases with high unmet medical need.
Arthro Kinetics Biotechnology GmbH: We develop, manufacture and distribute medical implants based on a proprietary and unique 3D Biomatrix from collagen type 1, which functions as a neutral organ scaffold for different types of cells. Today, our unique Matrix provides a proven three-dimensional cultivation environment for products and procedures to repair, to regenerate and to restore natural tissue function. With its applications, it proofs an extraordinary pathway since 2004.
We help ambitious clients with scaling and growth through digital success.